News

CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate

August 12, 2019

Oslo, Norway and Cambridge, MA, USA; August 12, 2019—The Coalition for Epidemic Preparedness Innovations (CEPI) and Public Health Vaccines, LLC. (PHV) have announced a partnering agreement worth up to US$ 43.6 million to advance the development and manufacture of a vaccine against the Nipah virus… Read More

Public Health Vaccines awarded advanced development contract from BARDA to develop vaccine against Marburg virus

March 5, 2019

CAMBRIDGE, MA – March 5, 2019 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has been awarded a contract for the advanced development of its vaccine candidate designed to prevent Marburg virus infections. PHV will leverage the proven recombinant vesicular stomatitis virus (rVSV) vector platform originally developed by the Public Health Agency of Canada (PHAC). Read More

Public Health Vaccines to develop vaccines against infectious disease threats, including Marburg virus and Sudan ebolavirus.

February 6, 2019

CAMBRIDGE, MA – February 6, 2019 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has entered into a license arrangement with the Public Health Agency of Canada (PHAC) to leverage the advanced recombinant vesicular stomatitis virus (rVSV) vector platform that PHAC discovered in 2005, to develop vaccines against Marburg virus and Sudan ebolavirus. Read More